IL25 and neoplasm: Collectively, these studies suggest that IL-25-mediated activation of ILC2s, and IL-33-mediated stimulation of Th2 cells, may act as independent parallel pathways to induce the production of IL-4 and IL-13 leading to the activation of MDSCs to suppress anti-tumour T cells and promote CRC.